Files

718809.pdf (571.93 KB)

Document type

Article

Version

Published version

Publication date

2021-12-01

Publication license

cc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/193208

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1136/jitc-2021-003644

Abstract

The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.

Subject

Leucèmia limfocítica crònica, Cèl·lules canceroses, Teràpia cel·lular, Antígens CD, Immunoteràpia, Receptors cel·lulars

Subject (English)

Chronic lymphocytic leukemia, Cancer cells, Cellular therapy, CD antigens, Immunotheraphy, Cell receptors

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

ORTIZ-MALDONADO GIBSON, Valentín, et al. Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. Journal for ImmunoTherapy of Cancer . 2021. Vol. 9, num. 12, pags. e003644. ISSN 2051-1426. [consulted: 14 of June of 2026]. Available at: https://hdl.handle.net/2445/193208

Export metadata

JSON - METS

Share record